share_log

Cantor Fitzgerald Reiterates Neutral on Oncternal Therapeutics, Maintains $1.3 Price Target

Benzinga ·  Sep 7, 2023 11:29

Cantor Fitzgerald analyst Li Watsek reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Neutral and maintains $1.3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment